2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
5 May 2021SV NewsThe Dementia Discovery Fund Appoints Luca Santarelli, M.D., a Proven Neuroscience Leader, as the New Chair of its Scientific Advisory Board
4 May 2021Portfolio NewsCumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund
15 April 2021Portfolio NewsAlchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics- 7 April 2021SV NewsThe Dementia Discovery Fund Significantly Enhances its Neuroscience R&D Expertise to Support its Portfolio
17 March 2021Portfolio NewsAmathus Therapeutics signs strategic collaboration with Merck to Develop Treatments for Neurodegenerative Diseases- 16 March 2021Portfolio NewsAlchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease
- 2 February 2021Portfolio NewsQurAlis Continues to Expand Leadership Team with Two Key Hires
6 January 2021Portfolio NewsRibometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics- 18 November 2020Portfolio NewsCaraway Therapeutics Receives Research Grant from The Michael J. Fox Foundation to Further Investigate the Function of the Lysosomal Ion Channel TMEM175 and Gene Variants Linked to Parkinson’s Disease
16 November 2020Portfolio NewsCerevance’s CVN058 Achieves Primary Endpoint in Phase 1b Schizophrenia Cognition Study
12 November 2020Portfolio NewsNitrome Biosciences Announces Formation of Scientific Advisory Board and Appointment of Former AbbVie Executive James Summers, Ph.D. to SAB Chairperson- 28 September 2020Portfolio NewsQurAlis named as one of Fierce Biotech's 2020 Fierce 15
